These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6280269)

  • 21. Clinical efficacy of cefotaxime in serious infections.
    Karakusis PH; Feczko JM; Goodman LJ; Hanlon DM; Harris AA; Levin S; Trenholme GM
    Antimicrob Agents Chemother; 1982 Jan; 21(1):119-24. PubMed ID: 6282202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients. German Multicentre Study Group.
    Höffken G; Pasold R; Pflüger KH; Finke J; Fauser AA; Szelenyi H; Wagner J
    J Antimicrob Chemother; 1999 Sep; 44(3):367-76. PubMed ID: 10511404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical evaluation of ceftriaxone in the pediatric field].
    Hoshina H; Hirosawa H; Mikuni K; Ichihashi H
    Jpn J Antibiot; 1984 Nov; 37(11):2027-33. PubMed ID: 6098699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of serious urological infections with cefotaxime compared to ampicillin plus netilmicin.
    Rasmussen D; Bremmelgaard A; Rasmussen F; Thorup J
    Dan Med Bull; 1986 Feb; 33(1):49-51. PubMed ID: 3948539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Carmine AA; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1983 Mar; 25(3):223-89. PubMed ID: 6303743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial.
    Li JT; Lu Y; Hou J; Chen YF; Miao JZ; Jia YX; Hou J; Zhang XZ; Chen DK; Hu WZ; Li LJ; Liu DM; Wang Z; Wu J; Gu JM; Wang HL; Zhang YL; Sun L
    Clin Infect Dis; 1997 Mar; 24(3):498-505. PubMed ID: 9114206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The use of cefotaxime against infections (author's transl)].
    Lepeu G; Bertrand A; Armengaud M; Aubertin J
    Nouv Presse Med; 1981 Feb; 10(8):594-7. PubMed ID: 6259600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli.
    Clergeot A; Steru D; Rosset MA; Carbon C
    Rev Infect Dis; 1991; 13 Suppl 7():S648-51. PubMed ID: 2068476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefmenoxime therapy of serious bacterial infections.
    Gombert ME; Glasser LA; Eng RH
    Antimicrob Agents Chemother; 1984 Apr; 25(4):510-2. PubMed ID: 6329082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sulbactam/ampicillin versus cefotaxime as initial therapy in serious soft tissue, joint and bone infections.
    Löffler L; Bauernfeind A; Keyl W
    Drugs; 1988; 35 Suppl 7():46-52. PubMed ID: 3265378
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ceftizoxime in the treatment of infective pathology in the elderly].
    Garotta F; Magni O; Meinardi G
    Boll Chim Farm; 1986 Dec; 125(12):127S-131S. PubMed ID: 3473994
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of ceftazidime in severe Gram-negative infections--a preliminary study.
    Clumeck N; Vanlaethem Y; Gordts B; Jaspar N; Butzler JP
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():317-21. PubMed ID: 19803007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftriaxone: in vitro studies and clinical evaluation.
    Gnann JW; Goetter WE; Elliott AM; Cobbs CG
    Antimicrob Agents Chemother; 1982 Jul; 22(1):1-9. PubMed ID: 6289734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Microbiologic and clinical significance of cefotiam].
    Tauchnitz C; Ezold R; Bauer I; Berger HD; Buhl C; Goedecke A; Morawietz I
    Z Gesamte Inn Med; 1985 Mar; 40(5):143-8. PubMed ID: 3857792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effectiveness of cefotaxime in pediatric infectious diseases].
    Takimoto M; Tasaki T; Kusunoki Y; Yoshioka H; Hiramoto A; Sanae N; Tsuchida A; Maruyama S; Mukai N; Takahashi Y
    Jpn J Antibiot; 1985 Jan; 38(1):107-13. PubMed ID: 3989970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative evaluation of cefmenoxime versus cefoxitin in serious infections.
    Bechard DL; Hawkins SH; Sutherland SC
    Am J Med; 1984 Dec; 77(6A):13-6. PubMed ID: 6097117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefotaxime for the treatment of gram-positive urinary tract infection.
    Piccinno A; Pagliarulo A
    Infection; 1985; 13 Suppl 1():S100-2. PubMed ID: 4055038
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical evaluation of cefmenoxime in internal medicine, with special reference to infections associated with hematological disorders].
    Uchida T; Matsuda S; Kimura H; Satoh T; Ishibashi T; Kokubun K; Umezu H; Horikawa A; Saitoh T; Sakauchi Y
    Jpn J Antibiot; 1984 Dec; 37(12):2506-18. PubMed ID: 6098743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefotaxime and cefazolin in the treatment of complicated urinary tract infections: a comparative study.
    Madsen PO; Iversen P
    Clin Ther; 1981; 4(1):7-11. PubMed ID: 6268298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tobramycin nephrotoxicity: failure of cefotaxime to potentiate renal toxicity.
    Kuhlmann J; Seidel G; Grötsch H
    Infection; 1982; 10(4):233-9. PubMed ID: 6127319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.